Recurrent Vulvovaginal and Oral Candidiasis with Post-Coital Flares
This patient requires confirmation of diagnosis with vaginal culture to identify the Candida species and assess for azole resistance, followed by extended induction therapy (7-14 days) and 6 months of weekly fluconazole maintenance therapy, with concurrent evaluation and treatment of her sexual partner. 1
Immediate Diagnostic Steps
The pattern of immediate post-coital flares strongly suggests either:
- Non-albicans Candida species (particularly C. glabrata, found in 10-20% of recurrent cases) 1, 2
- Azole-resistant C. albicans 3
- Partner recolonization
- Hypersensitivity reaction
Obtain vaginal cultures immediately - not just wet mount microscopy. C. glabrata doesn't form pseudohyphae and is easily missed on KOH prep 1, 2. Culture is essential because conventional azole therapies are significantly less effective against non-albicans species 1, 2.
Treatment Algorithm Based on Culture Results
If C. albicans (Most Likely - 74-80% of RVVC cases):
Induction Phase:
- Fluconazole 150 mg on days 1,4, and 7 (three doses total) 1, 2
- OR 7-14 days of topical azole therapy 1, 2
Maintenance Phase (Critical - Start Immediately After Induction):
- Fluconazole 150 mg once weekly for 6 months 1, 2, 4
- This reduces recurrence during treatment but 30-40% will relapse after discontinuation 2
If C. glabrata or Other Non-Albicans Species (20% of RVVC):
Fluconazole will likely fail. Use:
- First-line: 7-14 days of non-fluconazole topical azole (terconazole or butoconazole preferred) 1, 2
- If recurrence: Boric acid 600 mg vaginal capsules daily for 14 days (70% cure rate) 1, 2
- Alternative: Compounded 17% flucytosine cream ± 3% amphotericin B cream for 14 days 1
- Long-term suppression: Nystatin 100,000 units vaginal suppository daily 2
If Azole-Resistant C. albicans (Rare but Emerging):
Consider referral for:
- Oteseconazole (novel CYP51 inhibitor with 96% reduction in recurrence at 48 weeks) 5, 6, 7
- Ibrexafungerp (first-in-class triterpenoid) 6, 7
Critical Partner Management
The post-coital timing is the key clinical clue here. While routine partner treatment is controversial for RVVC 1, 2, this patient's immediate post-intercourse flares warrant:
- Examine partner for balanitis (erythematous glans with pruritus) 2, 8
- If symptomatic: Treat with topical antifungal (clotrimazole or miconazole cream) for 7 days 2, 8
- Consider empiric partner treatment even if asymptomatic, given the temporal relationship 2
- Recommend condom use during the 6-month maintenance phase to break the recolonization cycle
Oral Thrush Component
The concurrent oral candidiasis suggests possible:
- Immunocompromise (check HIV, diabetes, consider immunoglobulin levels if recurrent) 1
- Oral-genital transmission cycle
Treat oral thrush concurrently:
- Fluconazole 200 mg day 1, then 100 mg daily for 14 days 1
- This overlaps with the vaginal treatment regimen
Common Pitfalls to Avoid
Don't rely on wet mount alone - 10-20% of women colonized with Candida are asymptomatic; you need culture to confirm pathogenic infection and identify species 1, 8
Don't use single-dose fluconazole for RVVC - this is only for uncomplicated acute VVC 1, 4. Recurrent disease requires extended induction plus maintenance 1, 2
Don't ignore the pH - VVC should have pH ≤4.5. If pH >4.5, consider bacterial vaginosis or trichomoniasis as concurrent or alternative diagnosis 9, 8
Don't assume fluconazole resistance is common - it's rare in C. albicans vaginal isolates, but surveillance is prudent in treatment failures 2
Don't forget that antifungal MICs are pH-dependent - drugs tested at laboratory pH 7 may show false susceptibility; actual vaginal pH 4 can increase MICs up to 388-fold for some agents (especially terconazole against C. glabrata) 5
Underlying Conditions to Screen
- Diabetes mellitus (check HbA1c) - uncontrolled hyperglycemia is a major risk factor 2, 10
- HIV testing if not recently done 2
- Review medications for recent antibiotics, corticosteroids, or immunosuppressants 8, 10
- Contraceptive use - some formulations increase risk 10
Expected Outcomes and Follow-Up
- During maintenance: 90-96% will remain symptom-free 5, 4
- After stopping maintenance: 30-40% will experience recurrence within months 2
- If symptoms persist despite appropriate therapy: Consider non-Candida etiology, contact dermatitis from treatments, or vulvodynia 5
Schedule follow-up at 1 month to confirm culture results and treatment response, then every 2-3 months during maintenance therapy 8. If recurrence occurs after completing 6 months of maintenance, consider extending to 12 months or indefinite suppression 2.
The post-coital pattern combined with oral involvement makes this case more complex than typical RVVC, warranting aggressive initial management and close monitoring for treatment failure that might indicate resistant organisms or immunocompromise.